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cis-trans isomerization of proteins phosphorylated
by proline-directed kinases is proposed to control
numerous signaling molecules and is implicated in
the pathogenesis of Alzheimer’s and other diseases.
However, there is no direct evidence for the exis-
tence of cis-trans protein isomers in vivo or for their
conformation-specific function or regulation. Here
we develop peptide chemistries that allow the gener-
ation of cis- and trans-specific antibodies and use
them to raise antibodies specific for isomers of phos-
phorylated tau. cis, but not trans, p-tau appears
early in the brains of humans with mild cognitive
impairment, accumulates exclusively in degenerated
neurons, and localizes to dystrophic neurites during
Alzheimer’s progression. Unlike trans p-tau, the cis
isomer cannot promote microtubule assembly, is
more resistant to dephosphorylation and degrada-
tion, and is more prone to aggregation. Pin1 converts
cis to trans p-tau to prevent Alzheimer’s tau
pathology. Isomer-specific antibodies and vaccines
may therefore have value for the early diagnosis
and treatment of Alzheimer’s disease.
INTRODUCTION
Reversible protein phosphorylation of serine or threonine resi-
dues preceding a proline (pSer/Thr-Pro) is a central signaling
mechanism in diverse cellular processes in physiology and
disease (Blume-Jensen and Hunter, 2001; Lu et al., 2002;
Nigg, 2001). Notably, certain pSer/Thr-Pro motifs in phospho-
peptides exist in two distinct cis and trans conformations (Yaffe
et al., 1997), and their isomerization is especially important
because Pro-directed kinases and phosphatases are cis or trans
conformation specific (Brown et al., 1999; Zhou et al., 2000).
Moreover, phosphorylation slows down their isomerization rate232 Cell 149, 232–244, March 30, 2012 ª2012 Elsevier Inc.and renders the peptide bond resistant to conventional pep-
tidyl-prolyl cis-trans isomerases (PPIases) (Yaffe et al., 1997;
Zhou et al., 2000). However, the PPIase Pin1 (Lu et al., 1996)
binds to and isomerizes specific pSer/Thr-Pro motifs in a subset
of proteins, leading us to hypothesize that Pin1 catalytically regu-
lates its substrate conformation after phosphorylation to control
protein function (Lu et al., 1999a, 1999b; Ranganathan et al.,
1997; Shenet al., 1998; Yaffe et al., 1997; Zhouet al., 1999, 2000).
Subsequent studies have provided supporting evidence for
postphosphorylation conformational regulation (Liou et al.,
2011; Lu and Zhou, 2007). For example, Pin1 greatly accelerates
isomerization of the APP intracellular domain between the two
distinct conformations, as visualized by nuclear magnetic reso-
nance (NMR) (Pastorino et al., 2006) and has profound effects
on a spectrum of activities of numerous signaling molecules
(Girardini et al., 2011; Liou et al., 2011; Lu and Zhou, 2007;
Theuerkorn et al., 2011; Tun-Kyi et al., 2011; Yuan et al., 2011).
Functionally, Pin1 regulates many cellular processes involving
Pro-directed phosphorylation, with an emerging theme that
Pin1 often acts on multiple targets to synergistically drive certain
cellular processes to a single direction (Liou et al., 2011; Lu
et al., 2007; Lu and Zhou, 2007). Importantly, Pin1 deregulation
contributes to an increasing number of diseases, notably cancer
and Alzheimer’s disease (AD) (Butterfield et al., 2006; Lee et al.,
2011b; Lu and Zhou, 2007). These Pin1 functions are abolished
by catalytically inactivating mutations (Lu and Zhou, 2007) or
DAPK1-mediated inhibitory phosphorylation (Lee et al., 2011a).
However, without a tool to detect cis- or trans-specific protein
conformation in the cell, there is no direct evidence for protein
cis-trans isomerization in vivo, or for isomer-specific regulation
of function (Liou et al., 2011; Lu and Zhou, 2007).
The neuropathological hallmarks of AD are tangles made of
hyperphosphorylated tau (p-tau) and plaques composed of
amyloid beta-peptides (Ab) derived from amyloid precursor
protein (APP) (Ballatore et al., 2007; Goedert and Spillantini,
2006; Mattson, 2004; Spires-Jones et al., 2009). It is increasingly
evident that tau pathology in ADmay result from the combination
of the detrimental effects of loss of normal tau function to
promote microtubule (MT) assembly and toxic gain of function
acquired by p-tau aggregates (Ballatore et al., 2007). A defining
early event that disrupts tau MT function and precedes tangle
formation and neurodegeneration in AD is increased tau
phosphorylation, especially on Ser/Thr-Pro motifs (Ballatore
et al., 2007; Goedert and Spillantini, 2006; Mattson, 2004;
Spires-Jones et al., 2009). Many kinases or phosphatases are
deregulated in AD brains, and modulating these enzymes can
affect AD-related phenotypes (Ballatore et al., 2007; Cruz and
Tsai, 2004; Dolan and Johnson, 2010). However, it is not clear
how such phosphorylation becomes pathogenic, or how to
control it.
Recently, we have found a pivotal role for Pin1 in protecting
against age-dependent neurodegeneration in AD (Lee et al.,
2011b). Pin1 binds to and isomerizes the pThr231-Pro motif in
tau and the pThr668-Pro motif in APP in vitro (Lu et al., 1999a;
Pastorino et al., 2006; Zhou et al., 2000). Furthermore, Pin1
restores p-tau regulation of MTs, and also promotes p-tau
dephosphorylation and degradation (Lim et al., 2008; Liou
et al., 2003; Lu et al., 1999a; Zhou et al., 2000). Pin1 also reduces
amyloidogenic APPprocessing and toxic Ab secretion (Pastorino
et al., 2006), and promotes p-APP degradation (Ma et al., 2012a).
Consequently, Pin1 knockout mice develop age-dependent tau-
and Ab pathologies, and neurodegeneration, resembling many
aspects of human AD (Liou et al., 2003; Pastorino et al., 2006).
By contrast, Pin1 overexpression in postnatal neurons effectively
inhibits tau pathology and neurodegeneration in AD mouse
models overexpressing human wild-type tau (Lim et al., 2008).
Significantly in human brains, Pin1 is highly expressed in most
neurons but is inhibited in mild cognitive impairment (MCI) and
AD neurons (Butterfield et al., 2006; Liou et al., 2003; Lu et al.,
1999a), whereas a Pin1 single-nucleotide polymorphism (SNP)
that prevents its downregulation is associatedwith delayedonset
of AD (Ma et al., 2012b). Notably, Thr231 phosphorylation is the
first of a sequential cascade of phosphoepitopes that appear
during pretangle formation in AD (Luna-Mun˜oz et al., 2007).
Thus, Pin1 might accelerate cis-to-trans isomerization to protect
against tau and Ab pathology in AD (Lu et al., 2007; Lu and Zhou,
2007). However, there is no evidence that Pin1 actually regulates
protein conformation in vivo in AD or in any other process.
To detect Pin1-catalyzed conformational changes, we have
developed peptide chemistries suitable for the generation of
antibodies that can distinguish cis from trans pThr231-Pro
conformation in p-tau. We provide direct evidence that Pin1
accelerates cis-to-trans conversion, preventing pathogenic cis
p-tau accumulation and tau pathology in AD.
RESULTS
Generation of cis and trans Conformation-Specific
Antibodies
Proline-directed phosphorylation is a central signaling mecha-
nism in the cell, but it is unknownwhether such a phosphoprotein
exists in cis and trans conformations in vivo. To address this
question, we developed a strategy to generate antibodies that
can distinguish cis from trans pThr231-Pro conformation in
p-tau. NMR analysis showed that only 9% of a synthetic tau
peptide containing the pThr231-Promotif exists in the cis confor-
mation (Figure 1A; Figure S1A available online), making it difficultto produce cis-specific antibodies. Therefore, we immunized
rabbits with a modified pThr231-Pro tau peptide that contains
a minimal structural change but has both cis and trans contents
high enough to produce cis- and trans-specific antibodies,
followed by separation using affinity purification and counterpur-
ification procedures to remove potential contamination with
cis- and trans-locked peptides, respectively (Figure 1B).
Because the five-membered carbonyl ring of proline allows
its peptide bonds to adopt cis and trans conformations, we
reasoned that replacing this ring with a six-membered ring con-
taining one additional methylene group, as seen in homoproline
(Pip), might increase the cis content and allow the generation of
antibodies that would recognize endogenous tau isomers. To
test this hypothesis, we used NMR analysis to determine the
cis and trans contents of modified tau peptides. Indeed,
a pThr231-Pip tau peptide contained 74% cis peptide (Figures
1A, S1A, and S1B). When immunizing rabbits, the pThr231-Pip
tau peptide produced antibodies that recognize endogenous
human and mouse tau (Figures 1E–1H). To separate cis- and
trans-specific antibodies, we synthesized a pThr231-Dmp (5,5-
dimethylproline) tau peptide as a cis-locked peptide because
Dmp locks a peptidyl-prolyl bond in cis (An et al., 1999), and
a pThr231-Ala tau peptide as a pure trans peptide because Ala
adopts only the trans conformation, as confirmed by NMR
(Figures 1A, S1C, and S1D).
After the antibody purification outlined in Figure 1B, the spec-
ificity of resulting cis- and trans-specific antibodies was first
verified using ELISA. Both cis (Figure 1C) and trans (Figure 1D)
antibodies specifically recognized their respective cis and trans
peptides, with essentially no cross-reactivity. Their calculated
Kd values for the respective cis and trans pT231-tau peptides
were 2.1 and 1.6 nM. Importantly, they did not recognize an un-
phosphorylated Thr231-Pro tau peptide, but both were strongly
reactive to a wild-type pThr231-Pro tau peptide, as expected
from the fact that cis and trans isomers in phosphopeptides
can be interchanged relatively easily (Pastorino et al., 2006;
Zhou et al., 2000). Thus, cis and trans pThr231-Pro tau anti-
bodies are highly conformation specific in vitro.
Next, to examine whether the cis and trans antibodies recog-
nize pThr231 in tau in vivo, we performed immunoblotting and
immunostaining analyses. When tau and its T231A mutant
were expressed in neuronal SY5Y cells, both antibodies recog-
nized wild-type tau but not its T231A mutant (Figure 1E), similar
to ELISA results (Figures 1C and 1D). Furthermore, robust cis
and trans immunostaining signals were detected in tau trans-
genic (Tau-Tg) mouse brains overexpressing wild-type human
tau, but not after dephosphorylation (Lu et al., 1999a) or in
tau knockout mouse brains (Figure 1F). When frontal cortical
sections from advanced AD patients were double immuno-
stained with the cis or trans polyclonal antibody and a mono-
clonal antibody recognizing total tau, all cis- or trans-positive
neurons were also positive for total tau, but not all total tau-posi-
tive neurons were also positive for either cis or trans p-tau (Fig-
ure 1G), indicating that some, but not all, of tau is phosphorylated
on Thr231, as expected. In addition, immunostaining signals of
both cis and trans pThr231-Pro antibodies in AD brains partially
colocalized with those of AT180 (Figure S1E) and TG3 (Fig-
ure S1F), two antibodies recognizing pT231-containing tauCell 149, 232–244, March 30, 2012 ª2012 Elsevier Inc. 233
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Figure 1. Generation of Antibodies that Distinguish cis pThr231-Pro p-Tau from trans
(A) Proline modifications increase the prevalence of the cis isomer, as determined by NMR.
(B) Scheme for antibody purification.
(C and D) Specific recognition of the cis and trans pThr231-Pro tau antibodies by cis (pThr231-Dmp) and trans (pThr231-Ala) peptides, respectively, whereas both
antibodies recognize wild-type pThr231-Pro (cis+trans) tau peptide.
(E) T231A point mutation abolishes the ability of cis or trans pThr231-Pro tau antibody to recognize tau in SY5Y cells.
(F) cis and trans-pThr231-Pro tau antibodies are tau and phosphorylation specific, as shown in Tau-Tg brains after dephosphorylation by CIP or in Tau knockout
mouse brains.
(G) cis and trans pThr231-Pro tau antibodies recognize tau in AD brains. White arrows and arrowheads indicate total tau-positive neurons with and without cis or
trans pThr231-Pro tau expression, respectively. Red arrows indicate the neurons shown in insets. Yellow arrows point to dystrophic neurites labeled with the cis,
and the blue arrow points to the almost exclusive neuronal body localization of the trans.
(H) cis and trans antibodies are conformation specific with little cross-reactivity in AD brain sections. Only the cis and trans antibodies that were preabsorbedwith
trans and cis peptides, respectively, show signals. Scale bar represents 20 mm.
See also Figure S1.
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(Jicha et al., 1997). Thus, cis and trans antibodies recognize
pT231-containing tau (pT231-tau) in vivo.
Finally to determine whether these immunostaining signals
are specific to cis or trans pT231-tau, we preabsorbed the anti-
body with cis, trans, or cis + trans pT231-tau peptide prior to
immunostaining of AD frontal cortex. Staining signals of the cis
antibody were abolished by preabsorption with the cis, but not
trans peptide and vice versa (Figure 1H). Of note, a monoclonal
antibody that recognized only the cis pThr231-Dmp tau peptide,
but not pThr231-Pro tau peptide in ELISA (Figure S1G) could not
generate any immunostaining signal in Tau-Tg mouse brains
(Figure S1H). Thus, cis and trans pT231-tau antibodies are
conformation and phosphorylation specific in vitro and in vivo.
cis, but Not trans, pT231-Tau Is a Very Early
Conformation Associated with AD Progression
In human AD, Thr231 phosphorylation is the first detectable tau
phosphorylation event (Luna-Mun˜oz et al., 2007), and its levels
track disease progress (Ewers et al., 2007; Hampel et al.,
2001). However, it is not known whether cis, trans, or both
pT231-tau conformations are elevated. Moreover, the involve-
ment of pT231-tau isomerization in MCI has not been tested.
Generation of the cis- and trans-specific antibodies provides
an opportunity to address these questions.
Immunostaining of human frontal cortical sections revealed
that tau protein was readily detected in normal neurons and total
amountswere increasedwith progression of neurodegeneration,
especially in AD brains (Figure 2A). Although very little, if any,
cis or trans pT231-tau signals were detected in 9 normal brains,
cis pT231-tau signals were dramatically increased in 11 AD
brains (Figure 2A). Strong cis, but not trans, pT231-tau was
detected in 4 out of 6 MCI cases (Figure 2A), with weaker but
clearly detectable cis signals in remaining 2 MCI cases (data
not shown).
To confirm the above results, we performed immunoblotting
analysis of frontal cortical lysates obtained from 9 normal
controls with Braak stages I and II, 6 MCI patients with Braak
stages III and IV, and 11 AD patients with Braak stage V and VI
to semiquantify their cis and trans pT231-tau contents. We
used cis and trans p-tau in tau-overexpressing SY5Y neuronal
cells as relative standards for comparison. Again, although
neither cis nor trans was detected in normal brains (Figure 2B),
cis pT231-tau was elevated in MCI brains and further accumu-
lated as the Braak stage progresses, with much smaller
increases in trans p-tau (Figures 2C and 2D). These results
suggest that cis pT231-tau is specifically elevated in MCI and
AD brains. Both cis and trans signals were detected by immuno-
blotting under denatured and native conditions (Figure S2A). The
ability to detect cis and trans pT231-tau conformations by immu-
nostaining and immunoblotting is perhaps surprising given the
disruptive nature of these techniques. However, many anti-
bodies raised against human AD paired helical filaments recog-
nize AD-specific abnormal p-tau conformations in immunostain-
ing and immunoblotting, suggesting that these conformations
are in fact rather stable (Davies, 2000).
The above results suggest that cis pT231-tau might be more
pathologically relevant, and this is further supported by the strik-
ingly different subcellular localizations of cis and trans p-tau inMCI and AD brains. Although both p-tau conformations were
found in neuron bodies in the frontal cortex, only cis pT231-tau
was detected in neurites of MCI and AD brains, with more and
more being accumulated in dystrophic neurites as the Braak
stage increased (Figures 1G, 2A, and S1F, yellow arrows).
Notably, p-tau in dystrophic neurites was also recognized by
the pT231 antibody AT180 (Figure S2B) and the total tau anti-
body DC25 (Figure S2C), with cis and AT180 signals being colo-
calized in the neurites (Figures S1E and S2C). In sharp contrast,
there was almost no or very little trans pT231-tau in dystrophic
neurites even in advanced AD brains (Figures 1G, 2A, and S1F,
blue arrows). Similar results were also confirmed using anti-
bodies raised in a different rabbit (Figure S1I). This different local-
ization pattern is likely pathologically significant given that
missorting of p-tau to neurites and synaptic loss in the frontal
cortex are early hallmarks of AD and are highly correlated with
cognitive loss in AD patients (Davies et al., 1987; DeKosky and
Scheff, 1990; Scheff et al., 1990). These results not only confirm
the specificity of the cis and trans antibodies but also indicate
that only cis, but not trans, pT231-tau localizes to pathologically
relevant dystrophic neurites.
Pin1 Restores the Ability of cis pT231-Tau to Promote
Microtubule Assembly
The above results suggest that cis, but not trans, pT231-tau
might be pathologically more relevant to MCI and AD. We
wondered whether cis and trans p-tau conformations might
have any differences in biological functions or biochemical prop-
erties relevant to tau pathology in AD, and whether they might be
regulated. Pin1 is the only enzyme known to isomerize the
pThr231-Pro motif in a tau peptide (Zhou et al., 2000), to restore
the ability of pT231-tau to promote MT assembly (Lu et al.,
1999a) and to promote pT231-tau dephosphorylation and degra-
dation (Lim et al., 2008; Liou et al., 2003; Lu et al., 1999a; Zhou
et al., 2000). Pin1 is inhibited by multiple mechanisms in human
MCI and AD neurons (Lee et al., 2011b). Indeed, Pin1 levels are
much lower in AD brains (Figures S3A and S3B) and in MAP2-
positive AD neurons (Figure S3C), suggesting that lower Pin1 is
unlikely due to cell death. Thus, Pin1 might protect against tau
pathology in AD by preventing the accumulation of the patho-
genic cis p-tau.
To examine this possibility, we first examined whether Pin1
would increase cis-to-trans isomerization of pT231-tau in vitro.
Both cis and trans pThr231-Pro signals were detected in tau
but not its T231A mutant after phosphorylation (Figures 3A–
3C). Importantly, adding Pin1 significantly increased trans but
reduced cis pT231-tau content. In this assay, there may be
two distinct functions embodied in Pin1: acceleration of cis-to-
trans isomerization of the pThr231-Pro motif by the PPIase
domain (Pastorino et al., 2006; Yaffe et al., 1997; Zhou et al.,
2000) and trans-specific binding of the pThr231-Pro motif to
the WW domain (Wintjens et al., 2001). When Pin1 was added,
free trans would bind to the WW domain, depleting free trans.
The PPIase would greatly accelerate cis-to-trans isomerization
to maintain their equilibrium. The overall effect of Pin1 is there-
fore to increase the total amount of trans relative to cis. Consis-
tent with this notion, WW domain mutant W34A Pin1 and PPIase
domain mutant K63A Pin1 did not change the content of cis orCell 149, 232–244, March 30, 2012 ª2012 Elsevier Inc. 235
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Figure 2. cis, but Not trans, pT231-tau Appears Early in MCI Brains and Further Accumulates and Localizes to Dystrophic Neurites as
AD Progresses
(A) There is little, if any, cis or trans pT231-tau signal in age-matched normal brains, but both are dramatically increased in AD brains (especially the cis form).
Strong cis, but not trans, pT231-tau was detected in MCI cases. Note that many dystrophic neurites (yellow arrows) are labeled with the cis, but not the trans,
which is almost exclusively located in neuronal cell bodies (blue arrows). Scale bars represent 20 mm.
(B–D) The cis form is much more abundant than the trans, especially in MCI. Frontal cortex lysates from AD and age-matched normal control (B), Braak stages III
and IV (MCI), and Braak stages V and VI (AD) (C) were subjected to immunoblotting analysis with cis and trans antibodies, with short and long exposures being
shown in top and bottom panels, respectively. Intensities of cis or trans signals of tau-overexpressed SY5Y cells and human brain tissues at each Braak stage
were semi-quantified, and the percentages of the signals of human samples relative to that of SY5Y cells were expressed as means ± SEM (D).
See also Figure S2.trans (Figure S3D). Thus, Pin1 catalyzes cis-to-trans isomeriza-
tion of pT231-tau in vitro.
We next examined whether such Pin1-catalyzed cis-to-trans
isomerization would affect the ability of p-tau to promote MT
assembly, a major tau function that is lost in AD (Ballatore
et al., 2007), using FITC-labeled tubulin, as described (Lu et al.,
1999a; Nakamura et al., 2001). As expected, MT assembly was
greatly increased by tau, but not Cdc2 phosphorylated tau,
which was restored by PP2A (Figures 3D and 3G). Furthermore,
Pin1 effectively restored the ability of p-tau to promote MT236 Cell 149, 232–244, March 30, 2012 ª2012 Elsevier Inc.assembly (Figures 3D and 3G). In contrast, Cdc2-treated
T231A tau could still promote MT assembly and its ability to
affect MT function was not affected by Pin1 (Figures 3E and
3H), indicating the essential role of T231 phosphorylation for
Pin1 to regulate p-tau. These results confirm the previous find-
ings that phosphorylation of tau on Thr231 by Cdc2 disrupts its
ability to promote MT assembly (Lu et al., 1999a), that Pin1
restores this function, (Lu et al., 1999a), and that the ability of
Pin1 to regulate MT function depends on T231 phosphorylation
(Lim et al., 2008; Zhou et al., 2000). More importantly, the ability
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Figure 3. trans, but Not cis, pT231-Tau Promotes
Microtubule Assembly
(A–C) Addition of Pin1 to p-tau decreases cis but increases
trans pThr231-Pro levels. Recombinant tau (A and B) and
its T231A mutant (B) were phosphorylated by Cdc2 or
control buffer and then incubated with Pin1 before sub-
jecting to immunoblotting analysis with conformation-
specific antibodies, with the relative signal intensities
being quantified (C).
(D–I) trans, but not cis, pT231-tau promotes MT assembly.
FITC-labeled tubulin was treated with wild-type or T231A
mutant tau, p-tau, p-tau+PP2A, or p-tau+Pin1, followed by
MT assembly assay and visualization using confocal
microscopy (D and E). Addition of Pin1 or PP2A restored
the ability of p-tau to promote MT assembly (D and G). The
ability of T231A-p-tau to promote MT assembly was not
affected by Pin1 addition (E and H). Incubation of Pin1-
treated p-tau with the trans, but not cis antibody blocksMT
assembly (F and I). Microtubule assembly of each treat-
ment relative to that of p-tau (G and H) and p-tau+Pin1 (I)
was quantified.
Error bars indicate mean ± SEM. See also Figure S3.of Pin1 to restore p-tau MT assembly function was fully blocked
by incubation of Pin1-treated p-tau with trans antibody, but not
cis antibody (Figures 3F and 3I). This effect of the trans antibody
was dependent on Pin1 action because application of trans or cis
antibody to p-tau without Pin1 did not affect MT assembly (Fig-
ure S3E). Thus, cis, but not trans, p-tau loses the ability to
promote MT assembly and Pin1 catalyzes cis-to-trans isomeri-
zation to restore this function.
cis pT231-Tau Is More Stable and More Prone
to Aggregation than trans pT231-Tau
In addition to loss of normal tau function, p-tau in AD is more
resistant to dephosphorylation and degradation and more prone
to protein aggregation, resulting in toxic gains of function (Balla-
tore et al., 2007). PP2A is a major Pro-directed Ser/Thr phos-
phatase in brain lysates that preferentially dephosphorylates
pSer/Thr-Pro motifs in trans in synthetic pT231-tau peptides,
as shown using chymotrypsin to chemically remove the trans
conformation (Zhou et al., 2000). To directly examine whether
cis pT231-tau is specifically resistant to dephosphorylation by
PP2A, we used the conformation-specific antibodies. trans,Cell 149, 2but not cis, pThr231-Pro tau peptide was readily
dephosphorylated by PP2A (Figure 4A), but they
both were rapidly dephosphorylated by CIP
(Figure 4B), a calf intestinal alkaline phospha-
tase that has no conformation specificity
toward its substrates (Zhou et al., 2000). More-
over, cis-locked pThr231-Dmp tau peptide
was much more resistant to dephosphorylation
by PP2A than trans pThr231-Pro tau peptide
(Figure S4A), although it was robustly dephos-
phorylated by CIP (Figure S4B). These results
provide further evidence that PP2A is a Pro-
directed phosphatase preferentially dephos-
phorylating pSer/Thr-Pro motifs in trans (Zhou
et al., 2000).Because Thr231 phosphorylation increases tau protein
stability and aggregation (Lim et al., 2008), we next compared
protein stability of cis and trans pT231-tau in neuronal cells
and mouse brains using a cycloheximide chase (Lim et al.,
2008). cis p-tau was much more stable than the trans; after
12 hr, cis p-tau was not reduced, whereas trans p-tau was
reduced by 75% (Figures 4C and 4D). Given the ability of
Pin1 to increase trans but decrease cis p-tau protein (Figures
3A and 3C), we might expect that Pin1 knockdown would
increase cis, but decrease trans p-tau levels, as well as further
increase cis p-tau stability. Indeed, at time 0, cis increased, but
trans decreased in Pin1 knockdown cells, as compared to
control cells (Figures 4C and 4D). Furthermore, cis was signifi-
cantly more stable and had a longer half-life than trans in Pin1
KD SY5Y cells compared with control cells (Figures 4C and
4D). Essentially the same results were obtained when inhibitors
of CDKs, JNKs, and GSK-3, which are implicated in phosphory-
lation of tau on Thr231, were added together with CHX to assess
preexisting p-tau (Figure S4C). In brain slice cultures from Tau-
Tg mice, cis p-tau had a longer half-life than the trans, being
24 versus 6 hr (Figures 4E and 4F). Thus, cis p-tau is more32–244, March 30, 2012 ª2012 Elsevier Inc. 237
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Figure 4. cis pT231-Tau Is More Resistant to Protein Dephosphorylation and Degradation andMore Prone to Protein Aggregation than trans
(A and B) cis pT231-tau is more resistant to dephosphorylation by PP2A but not CIP.
(C and D) cis pT231-tau is more stable than the trans and Pin1 KD increases cis but reduces trans in neuronal cells.
(E and F) cis pT231-tau is more stable than the trans in brain slice cultures of Tau-Tg mice.
(G–L) cis pT231-tau ismore prone to protein aggregation than the trans in Tau-Tgmouse brains (G andH) and humanMCI brains (I–L) for total tau (tau5) (I and J), or
cleaved tau (tauC3) (K and L), as determined by the sarcosyl fractionation. The amounts of cis and the trans in the insoluble fraction relative to the soluble fraction
were quantified (H, J, and L).
Error bars indicate mean ± SEM. See also Figure S4.stable than the trans in vitro and in vivo, and Pin1 converts cis to
trans to promote p-tau turnover.
To examine the effects of p-tau conformations on its aggrega-
tion, we compared the contents of cis and trans pT231-tau in sar-
cosyl-soluble and -insoluble fractions. In Tau-Tg mouse brains,
trans p-tau was almost all in the soluble fraction, with very little,
if any insoluble trans (Figures 4G and 4H). However, cis p-tau
was found almost equally between the insoluble and soluble
fractions (Figures 4G and 4H). Similar results were also obtained
in human MCI brains. As compared with trans p-tau, the cis was
found much more in the insoluble fraction than in the soluble
fraction for total p-tau and cleaved p-tau (de Calignon et al.,238 Cell 149, 232–244, March 30, 2012 ª2012 Elsevier Inc.2010) (Figures 4I–4L), indicating that cis p-tau is more prone to
protein aggregation.
The above results suggest that cis pT231-tau in Tau-Tg
mouse brains and human AD brains might be stable under
denaturing conditions. Indeed, cis pT231-tau in the insoluble
fraction of Tau-Tg mouse brains was recognized by cis, but
not trans, antibody in immunoblotting independently of whether
the samples were treated with SDS and boiled (Figure S4D).
Furthermore, when we used cis antibody to immunoprecipitate
cis pT231-tau from the insoluble fraction of AD brains, cis
pT231-tau exhibited a range of molecular weights bigger
than IgG (Figures S4E and S4F), and was detected only by cis
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Figure 5. cis, but Not trans, pT231-Tau Is Associated with Neurofibrillary Degeneration in the AD Hippocampus
(A–E) cis, but not trans, pT231-tau is correlated with reduced Pin1 levels. CA2 (A) and CA1 (B) subregions of the AD hippocampus were immunostained with Pin1
and cis or trans antibody. Relative Pin1 levels (C) and the numbers of cis- or trans-positive neurons in the CA2 (D) or CA1 (E) region are quantified. In the CA2
subregion where Pin1was highly expressed, trans-positive neuronswere dominant (A, C, andD), but in theCA1 subregionwhere Pin1was barely expressed, both
cis- and trans-positive cells were found (B, C, and E).
(F–I) cis, but not trans, pT231-tau signals are fully overlapped with PHF-1 signals. Double immunostaining images of cis or trans antibody with PHF-1 in the CA2
(F and G) and CA1 (H and I) regions showed that all cis-positive cells were also PHF-1 positive in both CA2 and CA1 regions, but 74% of trans-positive cells in the
CA2 region were not positive for PHF-1. Arrows indicate trans-positive and PHF-1-negative neurons.
Scale bars represent 20 mm. Error bars indicate mean ± SEM. See also Figure S5.and total tau antibodies, but not by trans antibody (Figure S4F).
Thus, cis p-tau is more resistant to dephosphorylation and
degradation and more prone to aggregation than the trans
isomer.
cis, but Not trans, pT231-Tau Correlates with
Neurofibrillary Degeneration in the AD Hippocampus
The above results indicate that cis, but not trans, pT231-tau not
only localizes to the pathologically relevant subcellular location
but also displays both losses of tau normal function as well as
gains of toxic function. A critical question is whether Pin1 regu-
lates the isomerization of pT231-tau in neurons in vivo.
To address this question, we started with investigating the
relationship between Pin1 levels and cis or trans pT231-tau
levels in subregions of the AD hippocampus. As shown (Liou
et al., 2003), we found that Pin1 was highly expressed in the
CA2 region but was dramatically reduced in the CA1 region
(Figures 5A–5C and S5A). Furthermore, neurons that were posi-
tive for PHF-1, a marker of neurofibrillary neurodegeneration in
AD, were prevalent in the CA1 but not CA2 region (Figures 5F,5H, S5B, and S5C), as documented (Liou et al., 2003). Impor-
tantly, in the CA2 region where Pin1 was highly expressed,
trans-positive neurons were dominant and only few cis-positive
neurons were detected (Figures 5A, 5D, and S5A). However, in
the CA1 region where Pin1 was barely expressed, cis-positive
neurons were greatly increased with the number similar to that
of trans-positive neurons (Figures 5B, 5E, and S5A). The Pin1-
catalyzed cis-trans conversion in vivo is likely because both cis
and trans forms were present in the same neurons, as demon-
strated by immunostaining of two mirror sections of the AD
hippocampus with cis or trans antibody and total tau antibody
as a common indicator (Figure S5D).
More importantly, almost all cis-positive cells were also posi-
tive for PHF-1 in both CA2 (Figures 5F and 5G) and CA1 regions
(Figures 5H and 5I). However, 74% of trans-positive cells in the
CA2 region were negative for PHF-1 (Figures 5F and 5G), with
only 26% trans-positive cells being positive, which might be ex-
pected because Thr231 is unlikely to be the only phosphorylation
site that contributes to neurofibrillary neurodegeneration in AD.
Thus, cis, but not trans, pT231-tau is fully overlapped withCell 149, 232–244, March 30, 2012 ª2012 Elsevier Inc. 239
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Scale bars represent 20 mm. Error bars indicate mean ± SEM. See also Figure S6.neurofibrillary degeneration and also correlated with reduced
Pin1 levels in the AD hippocampus.
Pin1 Promotes cis-to-trans Isomerization of pT231-Tau
in AD Mouse Models
The above results suggest that Pin1 might prevent the accumu-
lation of the pathogenic cis pT231-tau in the brain. To directly
test the possibility, we examined the effects of Pin1 overexpres-
sion in postnatal neurons on the cis and trans contents of
pT231-tau by crossing Thy1-Pin1 transgenic (Pin1-Tg) mice
with Tau-Tg mice (Ishihara et al., 1999; Lim et al., 2008). Indeed,
Pin1 overexpression significantly increased trans pT231-tau but
reduced cis pT231-tau, when compared with littermates that
only overexpressed tau, as normalized using total tau (tau5 anti-
body) (Figures 6A and 6B) or total protein (tubulin antibody)
(Figure S6A). These results were further confirmed by immuno-
staining of the cerebral cortex (Figures 6C and 6D). Thus Pin1
overexpression reduces cis but increases trans pT231-tau levels
in mouse brains, consistent with its ability to increase cis-to-240 Cell 149, 232–244, March 30, 2012 ª2012 Elsevier Inc.trans conversion in vitro (Figures 3A and 3C) and to suppress
neurofibrillary neurodegeneration in mice (Lim et al., 2008).
To finally determine whether endogenous Pin1 is a rate-
limiting factor that controls the levels of cis and trans pT231-
tau conformations in vivo, we determined the effects of Pin1
knockout on cis and trans contents of pT231-tau by crossing
Pin1 knockout mice with Tau-Tg mice. Both immunoblotting
(Figures 6E, 6F, and S6B) and immunostaining (Figures 6G and
6H) analyses showed that loss of Pin1 function significantly
increased cis pT231-tau but decreased trans pT231-tau in
brains. These results are consistent with the ability of Pin1
knockout to induce tau pathology and neurodegeneration (Liou
et al., 2003), in contrast to the effect of Pin1 overexpression
(Lim et al., 2008). These results were also confirmed in a condi-
tion where the intensities of the cis and trans signals are almost
identical between different Tau-Tg mouse groups (Figure S6C).
These results together indicate that cis, but not trans, pT231-
tau is the pathogenic conformation in MCI and AD but is con-
verted by Pin1 to the nonpathological trans, providing in vivo
structural evidence for how the isomerase Pin1 protects against
AD tau pathology.
DISCUSSION
Pin1-catalyzed cis-trans isomerization of pSer/Thr-Pro motifs is
proposed to regulate many physiological and pathological
processes, but there is no direct evidence for this function in vivo.
We have developed a technology to generate cis- and trans-
specific antibodies, providing evidence that cis, but not trans,
pT231-tau is pathogenic in MCI and AD and that Pin1 protects
against tau pathology by converting it to the nontoxic trans
form. These results provide a tool to study cis-trans prolyl isom-
erization and their conformation-specific function and regulation
and suggest novel conformation-specific diagnoses and thera-
pies for AD and other diseases.
Conformation-Specific Antibodies as a Tool to Study
cis-trans Prolyl Isomerization
Emerging evidence suggests that both phosphorylation-depen-
dent and -independent cis-trans prolyl isomerization functions
as a molecular timer in many biological and pathological
processes (Lu et al., 2007; Theuerkorn et al., 2011).Most of these
studies are based on structural analyses in vitro, in combination
with mutational analyses in cells. Until now, probably the most
direct evidence for cis- and trans-specific function of a protein
involved the replacement of the key Pro8 in the 5-HT3 receptor
with an unnatural Pro analog having varying cis or trans prefer-
ence. This was then assayed for 5-HT3-dependent activity in
Xenopus oocytes, leading the conclusion that cis-trans isomeri-
zation switches the channel on or off (Lummis et al., 2005).
However, the functions of endogenous cis and trans proteins still
remain to be determined.
To apply the above approach to study conformational
regulation after phosphorylation would be challenging, if not
impossible, because such Pro analog motifs are unlikely to be
phosphorylated in vivo to become Pin1 substrates (Brown
et al., 1999). To detect Pin1-catalyzed protein conformational
changes, we reasoned that antibodies would only recognize
either cis or trans but not both isomers of a pSer/Thr-Pro motif
in a protein. This hypothesis was based on the completely
distinct structures of the two isomers of pThr688-Pro-containing
APP peptides revealed by NMR (Pastorino et al., 2006).
A key step to develop such conformation- and phospho-
specific antibodies is to increase the cis content of pSer/Thr-
Pro motifs in the antigen with the smallest change possible
because 90% of pSer/Thr-Pro motifs in a synthetic peptide
are in trans (Lu et al., 2007). We have here discovered that simply
increasing the Pro ring by one methylene group in a pT231-tau
peptide is sufficient to dramatically increase the cis content to
74% and, importantly, to generate phospho-specific antibodies
that recognize endogenous phosphoproteins. Moreover, we
have developed cis- or trans-locked peptides to purify cis- and
trans-specific antibodies. The resulting antibodies are highly
specific, with little cross-reactivity.We have since used this tech-
nology to successfully generate isomer-specific antibodies
against several other proteins (data not shown), and we believe
that this approach can be widely used to study cis- and trans-specific function and regulation of peptidyl-prolyl bonds,
including nonphosphorylated targets.
Conformation-Specific Localization, Biological
Function, and Pathological Significance in AD
We have uncovered striking differences in the subcellular local-
ization, biological function, and pathological significance of cis
and trans p-tau conformations in AD (Figure 7). Although neither
cis nor trans pT231-tau is detected in the healthy brain, cis, but
not trans, p-tau appears early in MCI neurons and further accu-
mulates as AD progresses. Furthermore, cis, but not trans, p-tau
is fully associated with neurofibrillary degeneration and also
localizes to pathologically relevant dystrophic neurites in AD
brains. Moreover, cis, but not trans, p-tau not only loses tau
normal function but also gains tau toxic function, two major
properties that are known to contribute to tau pathology in AD
(Ballatore et al., 2007). These results indicate that cis, but not
trans, p-T231-tau is pathogenic in AD.
cis-to-trans Isomerization Prevents Pathogenic p-Tau
Accumulation in AD
We have provided in vivo evidence that Pin1 protects against tau
pathology by converting pathogenic cis p-tau to the nonpatho-
genic trans form (Figure 7). These results provide a molecular
explanation for why Pin1 overexpression promotes tau dephos-
phorylation and degradation and inhibits tau aggregation and tau
pathology, whereas Pin1 knockout has the opposite effects in
model systems (Hamdane et al., 2006; Lim et al., 2008; Liou
et al., 2003). These results are highly relevant to human AD
because Pin1 is inhibited in MCI and AD neurons by multiple
mechanisms (Lee et al., 2011b), and preventing Pin1 inhibition
is associated with delayed AD onset (Ma et al., 2012b). Further-
more, Pin1 is phosphorylated and catalytically inactivated by
DAPK1 (Lee et al., 2011a), which is genetically linked to human
AD (Li et al., 2006) and whose deletion improves learning and
memory in mice (Yukawa et al., 2006). Thus, lack of sufficient
Pin1 to convert cis to trans contributes to pathogenic p-tau accu-
mulation and tau aggregation, eventually leading to tangle
formation and neurodegeneration in AD.
cis and trans Conformation-Specific Disease Diagnoses
and Therapies
Our findings suggest potential new approaches for early diag-
nosis and treatment of AD (Figure 7). For example, Thr231 phos-
phorylation is the first detectable phosphorylation event in
human AD (Luna-Mun˜oz et al., 2007), and its levels in cerebro-
spinal fluids tracks AD progression, but with large individual vari-
ations, limiting its suitability as a standardized test (Ewers et al.,
2007; Hampel et al., 2001). Our findings that cis, but not trans,
pT231-tau appears early in MCI and is pathogenic suggest that
cis pT231-tau and its ratio with trans might be a better and
more easily standardized biomarker, especially for early diag-
nosis and patient comparison. Overexpressing Pin1 or prevent-
ing Pin1 inhibition in neurons might be a valid approach to
prevent tau pathology during the earliest stages of AD by
reducing the cis-to-trans pT231-tau ratio. Finally, active or
passive immunization against some pSer/Thr-Pro motifs in tau
including the pThr231-Pro motif can reduce tau aggregatesCell 149, 232–244, March 30, 2012 ª2012 Elsevier Inc. 241
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Figure 7. Pin1 Prevents the Accumulation of the Pathogenic cis pT231-tau Conformation in AD by Converting It to the Nonpathogenic
trans Form
pT231-tau protein exists in the two completely distinct cis and trans conformations, as depicted in cartoons of the primary backbone structures. cis, but not trans,
pT231-tau loses normal function and also gains toxic function. Pin1 prevents the accumulation of the pathogenic cis pT231-tau conformation in AD by converting
it to the nonpathogenic trans form. Conformation-specific antibodies and/or vaccines against the pathogenic cis pT231-tau might be developed for the diagnosis
and treatment of AD, especially during its early stages.and memory deficits in mouse models (Boimel et al., 2010;
Boutajangout et al., 2010, 2011). However, our findings that
cis, but not trans, pT231-tau is pathogenic and 90% of regular
synthetic pT231-tau peptides exist in the trans conformation
suggests that it might be more effective to develop conforma-
tion-specific vaccines or antibodies specifically targeting cis
pT231-tau for treating or even preventing AD during its early
stages. Given the critical role of Pin1 and other isomerases in
regulating many other proteins in physiology and disease (Lee
et al., 2011b; Liou et al., 2011; Theuerkorn et al., 2011), it will
be interesting to determine whether prolyl isomerization also
regulates these protein conformations and whether such confor-
mational switches might be exploited for developing novel
diagnostic and therapeutic procedures.
EXPERIMENTAL PROCEDURES
Synthesis of Tau Peptides
Peptides used for the experiments are wild-type phosphorylated Thr231-Pro
tau (KVAVVRpTPPKSPS), nonphosphorylatedThr231 tau (KVAVVRTPPKSPS),
cis lock-in phosphorylated Thr231-Dmp tau (KVAVVRpT(5,5-dimethyl-L-
proline)PKSPS), trans lock-in phosphorylated Thr231-Ala tau (P232A)(KVAV
VRpTAPKSPS), and phosphorylated Thr231-Homoproline (pThr231-Pip) tau
(CKKVAVVRpT(Pip)PKSPSSAK), which are synthesized by a commercial
source.
NMR Spectrometry
Amide region of TOCSY spectra of tau-derived peptides (sequence KVAVVR-
pT231-X232-PKSPS) were used. Pro, Pip, Dmp, or Ala was incorporated into242 Cell 149, 232–244, March 30, 2012 ª2012 Elsevier Inc.thesequence followingpThr231.Two-dimensional 1H-1HTOCSYspectra (mix-
ing time of 70 ms) were taken and the population of the cis isomer was deter-
minedbycomparingpeakvolumes.Peaksused included theg,b, andaprotons
of pThr231 as seen from the amide proton in both the cis and trans states. cis
and trans isomers were assigned by identifying characteristic through-space
NOEs between Thr231 and Xaa232 protons in 1H-1H ROESY spectra.
Production and Purification of Antibodies
Rabbitswere immunizedwith pThr231-Homoproline (pThr231-Pip) tau peptide
that was coupled to KLH with N-terminal Cys. The resulting sera were purified
with pThr231-Homoproline (pThr231-Pip) tau peptide. For the cis conforma-
tion-specific pT231-tau antibody, the resulting bound fraction was purified
twice with cis pThr231-Dmp tau peptide to collect the bound fraction, followed
by counterpurificationwith pThr231-Ala tau peptide. The unbound fractionwas
collected as the cis conformation-specific pThr231-Pro tau antibody. For the
trans-specific pThr231-Pro tau antibody, the antibody was purified twice with
wild-type pThr231-Pro tau peptide to collect the bound fraction, followed by
counterpurification with pThr231-Dmp tau peptide. The unbound fraction
was collected as the trans-specific pThr231-Pro tau antibody.
Human Brain Specimens
Brains from 11 patients with AD (Braak stage V and VI) (mean age ± standard
error of themean [SEM]: 78.4 ± 3.1 years old), 6 patients withMCI (Braak stage
III and IV) (84.4 ± 5.6), and 9 healthy controls (Braak stage I and II) (78.0 ± 6.5)
were used for theanalyses.All ADsubjectsmet theclinical, andneuropatholog-
ical National Institute on Aging-Reagan Institute (NIA-RI) criteria, for AD. Our
studies for human samples have been approved by our Institutional Review
Board.
Transgenic Overexpression and Gene Knockout Mice
Tau-Tg mice (Ishihara et al., 1999), Tau-Tg+Pin1-Tg mice, and Tau-Tg+Pin1
KO mice in C57BL/6 background were generated, as described (Lim et al.,
2008; Liou et al., 2003). Tau knockout mice (Dawson et al., 2001) were
purchased from Jackson Laboratory. Animal care and use for the experiments
have been approved by our Institutional Animal Care and Use Committee.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
six figures and can be found with this article online at doi:10.1016/j.cell.
2012.02.016.
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